![](images/graphics/blank.gif)
Metastatic lung cancer
-
Metastatic disease is a major and difficult-to-treat complication of lung cancer. Considering insufficient effectiveness of existing therapies and taking into account the current problem of lung cancer chemoresistance, it is necessary to continue the development of new treatments.
14p
vishanshan
27-06-2024
2
1
Download
-
The impact of immune checkpoint inhibitors (ICIs) based treatments on non-small cell lung cancers (NSCLCs) with RET fusions remains poorly understood. Methods We screened patients with RET fusions at the First Affiliated Hospital of Zhengzhou University and included those who were treated with ICIs based regimens for further analysis.
9p
vikoch
27-06-2024
2
1
Download
-
Notwithstanding the diagnostic and therapeutic advancements, the incidence of cardiac metastases has increased in recent decades. Lung cancers are the most common primary malignant neoplasms with cardiac metastasis potential.
5p
vigojek
02-02-2024
3
1
Download
-
Pericardial neoplastic involvement is rarely related to primary tumors of the pericardium and is most often caused by spread from other primary sites, such as lung and breast carcinomas, hematological malignancies (lymphoma and leukemia), and melanoma.
4p
vilazada
31-01-2024
4
2
Download
-
Isolated pulmonary oligometastases as the first site of dissemination after initial resection of pancreatic ductal adenocarcinoma (PC) is a rare event, and the treatment in this subgroup is challenging. Recurrence in the lung after initial primary tumour resection is associated with the most long-term survivors of patients with metastatic PC.
7p
vitiki
30-01-2024
4
2
Download
-
Acrometastasis is an uncommon finding in non-small cell lung cancer and is usually a sign of multi-metastatic disease. Few case reports have suggested solitary digital metastasis as the single secondary lesion of oligo-metastatic non-small cell lung cancer.
4p
vitiki
30-01-2024
3
2
Download
-
The BRCA2 gene is a well-known tumor suppressor gene implicated in breast and ovarian cancers. BRCA1/2 mutations can be sensitive to poly ADP-ribose polymerase (PARP) inhibitors such as olaparib. However, some of these patients develop resistance to this treatment and an essential factor contributing to acquired insensitivity is the occurrence of reversion mutations in the BRCA1/2 genes.
5p
vitiki
30-01-2024
4
2
Download
-
Nutritional support, including nutritional counseling and oral nutritional supplements (ONS), has been recommended as a first-line strategy in patients with non-small cell lung cancer (NSCLC). Evidence on the efficacy of immunonutrition during immunotherapy in these patients is positive, but still limited some secondary endpoints, such as treatment toxicity and tolerance.
10p
vileonardodavinci
23-12-2023
4
2
Download
-
Currently, main treatment strategies for early-stage non-small cell lung cancer (ES-NSCLC) disease are surgery or stereotactic body radiation therapy (SBRT), with successful local control rates for both approaches.
7p
vileonardodavinci
23-12-2023
2
2
Download
-
Stereotactic radiosurgery (SRS) has become a standard approach for the treatment of patients with few metastatic brain lesions. This study aimed to compare the survival outcomes and intracranial local control in NSCLC patients with 1–4 BMs who are treated with SRS using linear accelerators (LINAC-SRS), whole-brain radiotherapy (WBRT), or WBRT plus radiotherapy boost (WBRT+RTB).
14p
vialfrednobel
23-12-2023
3
3
Download
-
Immunotherapy targeting the PD-1/PD-L1 pathway is a standard of care in a number of metastatic malignancies, but less than a fifth of patients are expected to respond to ICIs (Immune Checkpoint Inhibitors). In a clinical trial, combining the anti-TIGIT (T cell immunoreceptor with Ig and ITIM domains) Mab (monoclonal antibody) tiragolumab with atezolizumab improved outcomes in non-small cell lung cancer.
15p
vialfrednobel
23-12-2023
8
4
Download
-
As a potential target receptor tyrosine kinase, mesenchymal-epithelial transition factor (MET) exhibits high aberrant expression across various tumors. This study aimed to evaluated the safety, tolerability, efficacy and pharmacokinetics (PK) of BPI-9016M, a novel tyrosine kinase inhibitor (TKI) targeting c-MET, in c-MET overexpression or MET exon 14 skipping mutation patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC).
13p
vischultz
20-10-2023
3
1
Download
-
The CyberKnife system features a robotically-positioned linear accelerator to deliver real-time imageguided stereotactic ablative body radiotherapy (SABR). It achieves steep dose gradients using irradiation from hundreds of different directions and increases the central dose of the gross tumor volume (GTV) without increasing the marginal dose to the planning target volume.
10p
vischultz
20-10-2023
6
2
Download
-
Colorectal cancer (CRC) is one of the most prevalent types of malignant tumours. Metastasis is the leading cause of cancer-related mortality, with lung metastases accounting for 32.9% of all metastatic CRCs.
17p
vischultz
20-10-2023
5
1
Download
-
Pulmonary large cell neuroendocrine carcinoma (LCNEC) and small cell lung cancer (SCLC) are two types of high-grade neuroendocrine carcinomas of the lung with poor prognosis. LCNEC has not been thoroughly studied due to its rarity, data are also lacking regarding the survival comparison and prognosis analysis of patients with locally advanced or metastatic LCNEC and SCLC.
17p
vischultz
20-10-2023
2
1
Download
-
Over the past decade, there has been increasing availability of novel therapeutics with improved tolerability and efficacy for advanced non-small cell lung cancer (NSCLC). The study goals were: to compare the uptake of systemic therapy (ST) before and after the availability of targeted tyrosine kinase inhibitors (TKI) and immunotherapy and to examine the changes in overall survival (OS) over time between younger and older adults with advanced NSCLC.
11p
vischultz
20-10-2023
2
1
Download
-
The landscape of non-small cell lung cancer (NSCLC) therapy is rapidly changing. This analysis aimed to understand patient characteristics, diagnosis and treatment patterns in patients with metastatic NSCLC (mNSCLC) without EGFR and ALK mutations across fve European countries.
20p
vioracle
29-09-2023
4
3
Download
-
To analyze the EGFR mutation index on the cancer blocs of the patients with non - small cell lung cancer (NSCLC) at the Department of Pathology - Hue Central Hospital. Subjects and methods: A prospective, cross-sectional descriptive study of 227 patients with advanced, metastatic non - small cell lung cancer who were mutated in the EGFR gene. The study were carried out on the cancer parrafin blocs stored in Pathology Department, Hue Central Hospital.
5p
vinebula
02-06-2023
4
2
Download
-
The advent of immunotherapies has ushered in a new era in the treatment of non-small cell lung carcinoma. Although immunotherapies are associated with improved clinical outcomes, studies report a median overall survival of 11 months with progression-free survival of 2.5 months with the use of nivolumab for pretreated metastatic non-small cell lung cancer.
6p
vigamora
23-05-2023
7
3
Download
-
Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) are the current standard of care for advanced or metastatic non-small cell lung cancer (NSCLC) patients harboring EGFR activating mutations.
11p
vikolindagrabar
27-07-2022
5
2
Download
CHỦ ĐỀ BẠN MUỐN TÌM
![](images/graphics/blank.gif)